Dr. Eytan M. Stein

Dr. Eytan M. Stein, MD, is a highly regarded hematologic oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center (MSKCC), where he serves as Chief of the Leukemia Service and Director of the Program for Drug Development in Leukemia. He earned his medical degree from Northwestern University Feinberg School of Medicine, followed by an internal medicine residency at NYU Langone Health and a hematology-oncology fellowship at MSKCC. Board-certified in internal medicine, hematology, and medical oncology, Dr. Stein provides expert, personalized care to patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and related hematologic malignancies.

Dr. Stein is known for his pioneering contributions to the development of novel targeted therapies in leukemia, particularly early-phase clinical trials. His work has been instrumental in the advancement of IDH1/2 and FLT3 inhibitors, reshaping treatment options for patients with previously limited alternatives. His research explores the molecular drivers of AML and MDS, treatment resistance mechanisms, and biomarker development for precision oncology. Dr. Stein has authored more than 150 peer-reviewed articles and is a regular presenter at national and international oncology meetings.

Beyond his clinical and research roles, Dr. Stein is a committed educator and mentor, training the next generation of oncologists and clinical researchers. He serves on key national panels and cooperative groups dedicated to hematologic malignancies and experimental therapeutics. Through his leadership in translational research, clinical innovation, and patient-centered care, Dr. Stein continues to shape the future of leukemia treatment and stands as a trusted figure in modern hematologic oncology.